The safety of osteoporosis medication
| Autor: | W De Lange, Graham Ellis, T. J. de Villiers, F S Hough, Mkhululi Lukhele, Bilkish Cassim, Mike Davey, John M. Pettifor, Stan Lipschitz, S.L. Brown |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Fracture risk
Calcitonin Diarrhea medicine.medical_specialty Osteoporosis Alternative medicine Disease Thiophenes Fractures Bone Teriparatide medicine Esophagitis Humans Vitamin D Intensive care medicine Osteoporosis Postmenopausal Hip fracture Bone Density Conservation Agents Diphosphonates business.industry Estrogen Replacement Therapy General Medicine medicine.disease Cardiovascular Diseases Physical therapy Bisphosphonate-Associated Osteonecrosis of the Jaw Calcium business Constipation |
| Zdroj: | South African Medical Journal; Vol 104, No 4 (2014); 279-282 SAMJ: South African Medical Journal, Volume: 104, Issue: 4, Pages: 279-282, Published: APR 2014 |
| ISSN: | 0256-9574 2078-5135 |
| Popis: | Osteoporosis is a common, costly and serious disease, which is still too often regarded as an inevitable part of the normal ageing process and therefore sub-optimally treated, especially in the elderly – in fact, only two out of every 10 patients who sustain a hip fracture receive any form of assessment or prophylactic therapy for osteoporosis. One out of five patients die within 1 year after a hip fracture, and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|